Status:
COMPLETED
Convalescent Plasma in the Treatment of COVID 19
Lead Sponsor:
Trinity Health Of New England
Conditions:
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
COVID
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening ...
Detailed Description
The purpose of this prospective interventional study is to gain clinical experience using convalescent plasma transfusion administered to critically ill patients with COVID-19. 1 To study the efficac...
Eligibility Criteria
Inclusion
- All genders
- Age \> 18 yrs and \< 90 yrs
- Must have laboratory confirmed COVID-19
- Must provide informed consent
- Must have severe or immediately life-threatening COVID-19,
- Severe disease is defined as:
- dyspnea,
- respiratory frequency ≥ 30/min,
- blood oxygen saturation ≤ 93%,
- partial pressure of arterial oxygen to fraction of inspired oxygen ratio \< 300
- lung infiltrates \> 50% within 24 to 48 hours
- Life-threatening disease is defined as:
- respiratory failure,
- septic shock
- multiple organ dysfunction or failure
Exclusion
- No gender exclusion
- Age \< 18 yrs and \> 90 yrs
- COVID-19 negative
Key Trial Info
Start Date :
April 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 13 2020
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04343261
Start Date
April 10 2020
End Date
August 13 2020
Last Update
September 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Trinity Health Of New England
Hartford, Connecticut, United States, 06105